Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period (Q34818608)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period (English)

1 reference

Europe PubMed Central

4 August 2017

multicenter clinical trial

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

0 references

Gerd-Rüdiger Burmester

2

object named as

Gerd R Burmester

1 reference

Europe PubMed Central

4 August 2017

9

object named as

Tom W J Huizinga

1 reference

Europe PubMed Central

4 August 2017

Vivian P Bykerk

3

object named as

Vivian P Bykerk

1 reference

Europe PubMed Central

4 August 2017

author name string

Bernard G Combe

4

1 reference

Europe PubMed Central

4 August 2017

Daniel E Furst

5

1 reference

Europe PubMed Central

4 August 2017

Emilie Barré

6

1 reference

Europe PubMed Central

4 August 2017

Chetan S Karyekar

7

1 reference

Europe PubMed Central

4 August 2017

Dennis A Wong

8

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

3 November 2014

1 reference

Europe PubMed Central

4 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

4 August 2017

74

1 reference

Europe PubMed Central

4 August 2017

1

1 reference

Europe PubMed Central

4 August 2017

19-26

1 reference

Europe PubMed Central

4 August 2017

Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Progression in early rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Early rheumatoid arthritis -- is there a window of opportunity?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

8 July 2018

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206106

21 January 2018

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206106

21 January 2018

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206106

21 January 2018

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206106

21 January 2018

Prognostic markers of radiographic progression in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206106

21 January 2018

A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206106

21 January 2018

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206106

21 January 2018

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283672

26 October 2018

Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-206106

21 January 2018

Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/25367713

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/25367713

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the condu

1 reference

https://pubmed.ncbi.nlm.nih.gov/25367713

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25367713

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25367713

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2014-206106

1 reference

Europe PubMed Central

4 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34818608&oldid=1848269300"